Why the study?
Circulating biomarkers may identify at-risk individuals with diabetes who could benefit from SGLT2 inhibitors, but their role in modifying canagliflozin treatment benefits is unclear.
Does canagliflozin delay the rise of cardiac stress biomarkers and improve cardiovascular and renal outcomes in at-risk individuals with diabetes compared to placebo?
Cohort (n=563)
Does canagliflozin delay the rise of cardiac stress biomarkers and improve cardiovascular and renal outcomes in at-risk individuals with diabetes compared to placebo?
Answers are grounded in this paper and cite their sources.
Canagliflozin delays the longitudinal rise of cardiac stress biomarkers and reduces heart failure and kidney events regardless of baseline biomarker levels in patients with diabetes.
BACKGROUND: Circulating biomarkers reflecting different mechanistic pathways may identify at-risk individuals with diabetes who may benefit from sodium-glucose cotransporter-2 (SGLT2) inhibitors. OBJECTIVES: The purpose of this study was to determine if high-sensitivity cardiac troponin T (hs-cTnT), soluble suppression of tumorigenesis-2 (sST2), and insulin-like growth factor binding protein 7 (IGFBP7) levels, either alone or in combination, may modify the treatment benefits of canagliflozin. METHODS: In the CANVAS (CANagliflozin cardioVascular Assessment Study) biomarker substudy, we evaluated the prognostic significance of baseline biomarker measurements, the long-term trajectory of each, and response to canagliflozin on key cardiovascular and kidney outcomes. CONCLUSIONS: Canagliflozin delays longitudinal rise in hs-cTnT and sST2 compared with placebo out to 6 years. Canagliflozin reduced heart failure and kidney events regardless of baseline biomarker concentration. Elevated cardiovascular biomarkers, either alone or in combination, may identify individuals who may derive greater MACE benefit from SGLT2 inhibition. CANVAS (CANagliflozin cardioVascular Assessment Study; NCT01032629).
No takes yet. Share an insight, caveat, or question.
Vaduganathan et al. (2022) conducted a cohort in Congestive Heart Failure (n=563). COVID-19 pandemic period vs. Pre-pandemic period (March 2019-2020) was evaluated on Days to post-discharge follow up (p=0.0032).
Synapse has enriched 10 related papers. Consider them for comparative context: